In this week’s video, Dr. Brian Durie explains why MRD testing is important for assessing the results of clinical trials, but is not yet ready for the clinic.

BOTTOM LINE:
In clinical trials, the new criteria are essential to assess new drug combination therapies.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

 

Previous Post
Preview of the Black Swan Research Initiative’s First US Cure Trial
Next Post
Darzalex® (daratumumab): more very good news and a caution

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.